Targeted CRO ImQuest BioSciences operates as a preclinical CRO with expertise in virology, microbiology, oncology, and infectious disease, presenting opportunities to offer contract research services for antiviral, antibacterial, cancer, and inflammatory drug development programs seeking specialized preclinical validation and toxicity assessment.

Expansion Opportunity With a mid-sized team (11-50 employees) and revenues in the 10M-25M range, there is potential to scale collaborations through expanded formulation research, compound screening, and target validation services as clients move from discovery to preclinical optimization.

Diversified Modalities The portfolio spans small molecules, biologics, antimicrobial peptides, therapeutic antibodies, vaccines, and natural products, enabling cross-sell of services to partners pursuing multiple modalities across infectious disease and cancer pipelines.

Quality and Trust A focus on long-term client relationships, high-quality science, and clear communication signals readiness to engage in multi-year, multi-project CRO partnerships, including risk-sharing or milestone-based arrangements.

Recent Wins & Talent Historical recognitions as a best place to work and strategic hires in formulation R&D indicate a culture of excellence and capability growth, presenting a selling point for clients seeking reliable, innovative preclinical teams and strong project execution.